FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Pharmacol Ther / Pharmacokinetics of harpagoside in horses after intragastric...
Journal of veterinary pharmacology and therapeutics2018; 42(1); 37-44; doi: 10.1111/jvp.12716

Pharmacokinetics of harpagoside in horses after intragastric administration of a Devil’s claw (Harpagophytum procumbens) extract.

Abstract: Devil's claw is used for the treatment of inflammatory symptoms and degenerative disorders in horses since many years, but without the substantive pharmacokinetic data. The pharmacokinetic parameters of harpagoside, the main active constituent of Harpagophytum procumbens DC ex Meisn., were evaluated in equine plasma after administration of Harpagophytum extract FB 8858 in an open, single-dose, two-treatment, two-period, randomized cross-over design. Six horses received a single dose of Harpagophytum extract, corresponding to 5 mg/kg BM harpagoside, and after 7 days washout period, 10 mg/kg BM harpagoside via nasogastric tube. Plasma samples at certain time points (before and 0-24 hr after administration) were collected, cleaned up by solid-phase extraction, and harpagoside concentrations were determined by LC-MS/MS using apigenin-7-glucoside as internal standard. Plasma concentration-time data and relevant parameters were described by noncompartmental model through PKSolver software. Harpagoside could be detected up to 9 hr after administration. C was found at 25.59 and 55.46 ng/ml, t at 2.53 and 2.32 hr, respectively, and t at 1 hr in both trials. AUC was 70.46 and 117.85 ng hr ml , respectively. A proportional relationship between dose, C and AUC was observed. Distribution (V /F) was 259.04 and 283.83 L/kg and clearance (CL/F) 70.96 and 84.86 L hr  kg , respectively. Treatment of horses with Harpagophytum extract did not cause any clinically detectable side effects.
© 2018 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2018-09-22 PubMed ID: 30242850PubMed Central: PMC7379497DOI: 10.1111/jvp.12716Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Veterinary
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study investigates the pharmacokinetics, or how the body processes, a compound called harpagoside found in the plant Devil’s claw, commonly used for treating inflammatory and degenerative disorders in horses. The results showed that administration of Harpagophytum extract, containing this compound, in horses was generally safe and its properties could be measured up to 9 hours following administration.

Overview of the Research

  • This research was conducted to understand the pharmacokinetics of an active compound called harpagoside, which is derived from a plant named Devil’s claw or Harpagophytum procumbens. The plant extract has been used for many years to treat inflammatory and degenerative conditions in horses but prior to this research there were no detailed studies on just how it was processed in the body.
  • The scientists evaluated the pharmacokinetic parameters of the compound after administering a specific demon claw extract to six horses in a carefully designed experiment, involving a single dose followed by a washout period, and then a second, double dose. The study’s design ensured that any effects could be attributed to the plant extract.

Methodology and Findings

  • The extract corresponding to specific doses of harpagoside was administered to six horses via a nasogastric tube, which is a tube passed into the stomach via the nasal passage. The doses were determined based on the body weight of the horses.
  • Plasma samples were collected at specific time points before and after administration of the extract. The samples were cleaned up and the concentration of harpagoside was determined using a technique called LC-MS/MS, a sophisticated method that allows identification of specific compounds in biological samples.
  • The study revealed that harpagoside could be detected in the horses’ bodies up to 9 hours after administration, indicating that the extract was being effectively absorbed and remained in the system for a certain duration.
  • The scientists documented various pharmacokinetic parameters including peak concentration of the compound, time to reach peak concentration in the blood, the total amount of drug that entered the bloodstream, and the rate at which it was cleared from the body. Their findings were analysed using a software that specializes in analysing pharmacokinetic data.
  • The research concluded that administering horses with Harpagophytum extract is safe as it did not cause any observable side effects.

Cite This Article

APA
Axmann S, Hummel K, Nöbauer K, Razzazi-Fazeli E, Zitterl-Eglseer K. (2018). Pharmacokinetics of harpagoside in horses after intragastric administration of a Devil’s claw (Harpagophytum procumbens) extract. J Vet Pharmacol Ther, 42(1), 37-44. https://doi.org/10.1111/jvp.12716

Publication

Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
NlmUniqueID: 7910920
Country: England
Language: English
Volume: 42
Issue: 1
Pages: 37-44

Researcher Affiliations

Axmann, Sonja
  • Department of Farm Animals and Veterinary Public Health, Institute for Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine, Vienna, Austria.
Hummel, Karin
  • Technology Platform VetCore, University of Veterinary Medicine, Vienna, Austria.
Nöbauer, Katharina
  • Technology Platform VetCore, University of Veterinary Medicine, Vienna, Austria.
Razzazi-Fazeli, Ebrahim
  • Technology Platform VetCore, University of Veterinary Medicine, Vienna, Austria.
Zitterl-Eglseer, Karin
  • Department of Farm Animals and Veterinary Public Health, Institute for Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine, Vienna, Austria.

MeSH Terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / blood
  • Anti-Inflammatory Agents / pharmacokinetics
  • Cross-Over Studies
  • Female
  • Glycosides / blood
  • Glycosides / pharmacokinetics
  • Harpagophytum
  • Horses / blood
  • Horses / metabolism
  • Intubation, Gastrointestinal / veterinary
  • Male
  • Plant Extracts / administration & dosage
  • Plant Extracts / pharmacology
  • Pyrans / blood
  • Pyrans / pharmacokinetics
  • Random Allocation

Conflict of Interest Statement

The authors have no conflicts of interest.

References

This article includes 41 references
  1. Anauate MC, Torres LM, de Mello SB. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay.. Phytother Res 2010 Sep;24(9):1365-9.
    doi: 10.1002/ptr.3124pubmed: 20812280google scholar: lookup
  2. Baghdikian B, Lanhers MC, Fleurentin J, Ollivier E, Maillard C, Balansard G, Mortier F. An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri.. Planta Med 1997 Apr;63(2):171-6.
    doi: 10.1055/s-2006-957638pubmed: 9140234google scholar: lookup
  3. Beluche LA, Bertone AL, Anderson DE, Rohde C. Effects of oral administration of phenylbutazone to horses on in vitro articular cartilage metabolism.. Am J Vet Res 2001 Dec;62(12):1916-21.
    doi: 10.2460/ajvr.2001.62.1916pubmed: 11763181google scholar: lookup
  4. Boje K, Lechtenberg M, Nahrstedt A. New and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastase.. Planta Med 2003 Sep;69(9):820-5.
    pubmed: 14598207doi: 10.1055/s-2003-43225google scholar: lookup
  5. Chrubasik S. Addendum to the ESCOP monograph on Harpagophytum procumbens.. Phytomedicine 2004 Nov;11(7-8):691-5; author reply 696.
    doi: 10.1016/j.phymed.2004.03.003pubmed: 15636187google scholar: lookup
  6. Chrubasik JE, Lindhorst E, Neumann E, Gerlach U, Faller-Marquardt M, Torda T, Müller-Ladner U, Chrubasik S. Potential molecular basis of the chondroprotective effect of Harpagophytum procumbens.. Phytomedicine 2006 Sep;13(8):598-600.
    pubmed: 16500096doi: 10.1016/j.phymed.2006.01.014google scholar: lookup
  7. Chrubasik S, Model A, Black A, Pollak S. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain.. Rheumatology (Oxford) 2003 Jan;42(1):141-8.
    doi: 10.1093/rheumatology/keg053pubmed: 12509627google scholar: lookup
  8. Chrubasik S, Pollak S. [Pain management with herbal antirheumatic drugs].. Wien Med Wochenschr 2002;152(7-8):198-203.
    doi: 10.1046/j.1563-258X.2002.11115.xpubmed: 12017748google scholar: lookup
  9. Chrubasik S, Pollak S, Black A. Effectiveness of devil's claw for osteoarthritis.. Rheumatology (Oxford) 2002 Nov;41(11):1332-3; author reply 1333.
    doi: 10.1093/rheumatology/41.11.1332pubmed: 12422011google scholar: lookup
  10. Colas C, Garcia P, Popot MA, Bonnaire Y, Bouchonnet S. Liquid chromatography/electrospray ionization mass spectrometric characterization of Harpagophytum in equine urine and plasma.. Rapid Commun Mass Spectrom 2006;20(22):3257-66.
    doi: 10.1002/(ISSN)1097-0231pubmed: 17044124google scholar: lookup
  11. Colas C, Garcia P, Popot MA, Bonnaire Y, Bouchonnet S. Optimization of solid-phase extraction for the liquid chromatography-mass spectrometry analysis of harpagoside, 8-para-coumaroyl harpagide, and harpagide in equine plasma and urine.. J Chromatogr Sci 2008 Feb;46(2):174-83.
    doi: 10.1093/chromsci/46.2.174pubmed: 18366880google scholar: lookup
  12. ESCOP Monographs (2009). The scientific foundation for herbal medicinal products, 2nd ed. (pp. 135–146). Stuttgart: Thieme.
  13. Fiebich BL, Heinrich M, Hiller KO, Kammerer N. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69.. Phytomedicine 2001 Jan;8(1):28-30.
    doi: 10.1078/0944-7113-00002pubmed: 11292236google scholar: lookup
  14. Fiebich BL, Muñoz E, Rose T, Weiss G, McGregor GP. Molecular targets of the antiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1.. Phytother Res 2012 Jun;26(6):806-11.
    doi: 10.1002/ptr.3636pubmed: 22072539google scholar: lookup
  15. Georgiev M, Alipieva K, Pashova S, Denev P, Angelova M, Kerns G, Bley T. Antioxidant activity of Devil's Claw cell biomass and its active constituents. Food Chemistry 121, 967–972.
    doi: 10.1016/j.foodchem.2010.01.028google scholar: lookup
  16. Harman J. The toxicology of herbs in equine practice. Clinical Techniques in Equine Practice 8, 74–80.
    doi: 10.1053/ctep.2002.34475google scholar: lookup
  17. Huang TH, Tran VH, Duke RK, Tan S, Chrubasik S, Roufogalis BD, Duke CC. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation.. J Ethnopharmacol 2006 Mar 8;104(1-2):149-55.
    pubmed: 16203115doi: 10.1016/j.jep.2005.08.055google scholar: lookup
  18. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction.. Int J Cardiol 2005 Jan;98(1):1-14.
    doi: 10.1016/j.ijcard.2003.06.039pubmed: 15676159google scholar: lookup
  19. Jang MH, Lim S, Han SM, Park HJ, Shin I, Kim JW, Kim NJ, Lee JS, Kim KA, Kim CJ. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929.. J Pharmacol Sci 2003 Nov;93(3):367-71.
    doi: 10.1254/jphs.93.367pubmed: 14646256google scholar: lookup
  20. Inaba K, Murata K, Naruto S, Matsuda H. Inhibitory effects of devil's claw (secondary root of Harpagophytum procumbens) extract and harpagoside on cytokine production in mouse macrophages.. J Nat Med 2010 Apr;64(2):219-22.
    pubmed: 20177800doi: 10.1007/s11418-010-0395-8google scholar: lookup
  21. Lanhers MC, Fleurentin J, Mortier F, Vinche A, Younos C. Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens.. Planta Med 1992 Apr;58(2):117-23.
    doi: 10.1055/s-2006-961411pubmed: 1529021google scholar: lookup
  22. Lees P. Veterinary pharmacology: where to in the 21st century?. Vet J 2003 Mar;165(2):95-7.
    doi: 10.1016/S1090-0233(02)00177-6pubmed: 12573595google scholar: lookup
  23. Loew D, Möllerfeld J, Schrödter A, Puttkammer S, Kaszkin M. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo.. Clin Pharmacol Ther 2001 May;69(5):356-64.
    doi: 10.1067/mcp.2001.115445pubmed: 11372004google scholar: lookup
  24. Mahomed IM, Ojewole JA. Analgesic, antiinflammatory and antidiabetic properties of Harpagophytum procumbens DC (Pedaliaceae) secondary root aqueous extract.. Phytother Res 2004 Dec;18(12):982-9.
    doi: 10.1002/(ISSN)1099-1573pubmed: 15742343google scholar: lookup
  25. Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N. Devil's Claw-a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens.. J Ethnopharmacol 2012 Oct 11;143(3):755-71.
    doi: 10.1016/j.jep.2012.08.013pubmed: 22940241google scholar: lookup
  26. Montavon S. Efficacy of a phytotherapeutic preparation based on Harpagophytum procumbens in case of bone spavin of adult horses. Pratique Vétérinaire Équine 26, 49–53.
  27. Reed SK, Messer NT, Tessman RK, Keegan KG. Effects of phenylbutazone alone or in combination with flunixin meglumine on blood protein concentrations in horses.. Am J Vet Res 2006 Mar;67(3):398-402.
    doi: 10.2460/ajvr.67.3.398pubmed: 16506899google scholar: lookup
  28. Ritschel WA, Hammer GV. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption.. Int J Clin Pharmacol Ther Toxicol 1980 Jul;18(7):298-316.
    pubmed: 7429676
  29. Schaffer LF, Peroza LR, Boligon AA, Athayde ML, Alves SH, Fachinetto R, Wagner C. Harpagophytum procumbens prevents oxidative stress and loss of cell viability in vitro.. Neurochem Res 2013 Nov;38(11):2256-67.
    doi: 10.1007/s11064-013-1133-xpubmed: 23982320google scholar: lookup
  30. Schopohl P, Grüneberg P, Melzig MF. The influence of harpagoside and harpagide on TNFα-secretion and cell adhesion molecule mRNA-expression in IFNγ/LPS-stimulated THP-1 cells.. Fitoterapia 2016 Apr;110:157-65.
    doi: 10.1016/j.fitote.2016.03.005pubmed: 26979254google scholar: lookup
  31. Schulze-Tanzil G, Hansen C, Shakibaei M. [Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro].. Arzneimittelforschung 2004;54(4):213-20.
    pubmed: 15146934doi: 10.1055/s-0031-1296962google scholar: lookup
  32. Soulimani R, Younos C, Mortier F, Derrieu C. The role of stomachal digestion on the pharmacological activity of plant extracts, using as an example extracts of Harpagophytum procumbens.. Can J Physiol Pharmacol 1994 Dec;72(12):1532-6.
    doi: 10.1139/y94-220pubmed: 7736345google scholar: lookup
  33. Stewart KM, Cole D. The commercial harvest of devil's claw (Harpagophytum spp.) in southern Africa: the devil's in the details.. J Ethnopharmacol 2005 Sep 14;100(3):225-36.
    doi: 10.1016/j.jep.2005.07.004pubmed: 16112533google scholar: lookup
  34. Toutain PL, Lassourd V. Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse.. Equine Vet J 2002 May;34(3):242-9.
    pubmed: 12108741doi: 10.2746/042516402776185985google scholar: lookup
  35. Trumble TN. The use of nutraceuticals for osteoarthritis in horses.. Vet Clin North Am Equine Pract 2005 Dec;21(3):575-97, v-vi.
    pubmed: 16297722doi: 10.1016/j.cveq.2005.08.004google scholar: lookup
  36. Uchida S, Hirai K, Hatanaka J, Hanato J, Umegaki K, Yamada S. Antinociceptive effects of St. John's wort, Harpagophytum procumbens extract and Grape seed proanthocyanidins extract in mice.. Biol Pharm Bull 2008 Feb;31(2):240-5.
    doi: 10.1248/bpb.31.240pubmed: 18239280google scholar: lookup
  37. Van Haelen M, Van Haelen Fastré R, Samaey‐Fontaine J, Elchamid A, Niebes P, Matagne D. Aspects botaniques, constitution chimique et activité pharmacologique d′Harpagophytum procumbens. Phytotherapy 5, 7–13.
  38. Van Wyk B, Gericke N. Peoples Plants. A Guide to Useful Plants of Southern Africa. .
  39. Wegener T, Lüpke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.).. Phytother Res 2003 Dec;17(10):1165-72.
    doi: 10.1002/ptr.1322pubmed: 14669250google scholar: lookup
  40. Williams CA, Lamprecht ED. Some commonly fed herbs and other functional foods in equine nutrition: a review.. Vet J 2008 Oct;178(1):21-31.
    doi: 10.1016/j.tvjl.2007.06.004pubmed: 17689992google scholar: lookup
  41. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.. Comput Methods Programs Biomed 2010 Sep;99(3):306-14.
    doi: 10.1016/j.cmpb.2010.01.007pubmed: 20176408google scholar: lookup

Citations

This article has been cited 6 times.
  1. Gxaba N, Manganyi MC. The Fight against Infection and Pain: Devil's Claw (Harpagophytum procumbens) a Rich Source of Anti-Inflammatory Activity: 2011-2022. Molecules 2022 Jun 6;27(11).
    doi: 10.3390/molecules27113637pubmed: 35684573google scholar: lookup
  2. Brendler T. From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil's Claw (Harpagophytum spp.). Pharmaceuticals (Basel) 2021 Jul 27;14(8).
    doi: 10.3390/ph14080726pubmed: 34451822google scholar: lookup
  3. Luo S, Xie L, Chen J, Tang C, Xu RA. Determination and Pharmacokinetic Profiles of Four Active Components From Scrophularia ningpoensis Hemsl. in Rats. Front Pharmacol 2020;11:612534.
    doi: 10.3389/fphar.2020.612534pubmed: 33519478google scholar: lookup
  4. Nam HH, Lee AY, Seo YS, Park I, Yang S, Chun JM, Moon BC, Song JH, Kim JS. Three Scrophularia Species (Scrophularia buergeriana, S. koraiensis, and S. takesimensis) Inhibit RANKL-Induced Osteoclast Differentiation in Bone Marrow-Derived Macrophages. Plants (Basel) 2020 Nov 26;9(12).
    doi: 10.3390/plants9121656pubmed: 33256150google scholar: lookup
  5. Fang N, Wang Z, Jiang J, Yang A, Mao T, Wang Z, Chen Q. Nonsurgical therapy for lumbar spinal stenosis caused by ligamentum flavum hypertrophy: A review. Medicine (Baltimore) 2024 Jul 5;103(27):e38782.
    doi: 10.1097/MD.0000000000038782pubmed: 38968524google scholar: lookup
  6. Seo YS, Song JH, Kim HS, Nam HH, Yang S, Choi G, Chae SW, Lee J, Jung B, Kim JS, Park I. An Integrative Study of Scrophularia takesimensis Nakai in an Ovalbumin-Induced Murine Model of Asthma: The Effect on T Helper 2 Cell Activation. Pharmaceutics 2024 Apr 12;16(4).
    doi: 10.3390/pharmaceutics16040529pubmed: 38675190google scholar: lookup
Subscribe to our newsletter
Join 99,265 horse owners like you who receive our email updates on horse health and nutrition.